Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 17/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 15/20 | 0.38 |
| ▸ | PTGIR | P43119 | 4/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365458 | 1.00 | PTGFR (0.38) | PTGFRPTGER3PTGIRPTGER4PTGER2 | |
| SCHEMBL12640069 | 1.00 | PTGFR (0.38) | PTGFRPTGER3PTGIRPTGER4PTGER2 | |
| SCHEMBL10015897 | 0.92 | PTGFR (0.32) | PTGFRPTGER3PTGIRABCB11AKR1C3 | |
| SCHEMBL16766328 | 0.90 | PTGFR (0.38) | PTGFRPTGER3PTGIRPTGER4PTGER2 | |
| SCHEMBL16766327 | 0.90 | PTGFR (0.38) | PTGFRPTGER3PTGIRPTGER4PTGER2 | |
| SCHEMBL16788258 | 0.90 | PTGFR (0.38) | PTGFRPTGER3PTGIRPTGER4PTGER2 | |
| SCHEMBL18142101 | 0.90 | PTGFR (0.38) | PTGFRPTGER3PTGIRPTGER4PTGER2 | |
| SCHEMBL13584820 | 0.90 | PTGFR (0.31) | PTGFRPTGER3ABCB11AKR1C3 | |
| SCHEMBL12087459 | 0.90 | PTGFR (0.31) | PTGFRPTGER3ABCB11AKR1C3 | |
| SCHEMBL13584822 | 0.90 | PTGFR (0.31) | PTGFRPTGER3ABCB11AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288179-A1 | BIMATOPROST CRYSTALLINE FORM I | FINETECH PHARMACEUTICAL LTD. (IL) | 2011-11-24 | — | — | US | disclosed |
| US-7947740-B2 | Bimatoprost crystalline form I | FINETECH PHARMACEUTICAL LTD (IL) | 2011-05-24 | — | — | US | disclosed |
| US-20090163596-A1 | Bimatoprost crystalline form I | FINETECH PHARMACEUTICAL LTD. (IL) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163596-A1 | Bimatoprost crystalline form I | PTGER1, BBC3, CYP2A7 | PTGFR 28/4885PTGER3 14/4885PTGIR 37/4885 |
| US-20110288179-A1 | BIMATOPROST CRYSTALLINE FORM I | PTGER1, BBC3, CYP2A7 | PTGFR 28/4885PTGER3 14/4885PTGIR 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.